Twist Bioscience Becomes Digital Preservation Coalition Supporter

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced it has become a part of the Digital Preservation Coalition’s (DPC) Supporter Program, where members and solution providers can collaborate.

The Digital Preservation Coalition is a membership-based organization, established in 2002 initially as a collaboration between a number of agencies operating in the UK and Ireland, now with global membership. The DPC works to enable its members to deliver resilient long-term access to digital content and services to derive enduring value from digital assets and raises awareness of the strategic, cultural and technological challenges their members face.

“Our members store immensely rich and valuable cultural and organizational data, with much of that data archived for a long period of time,” commented William Kilbride, executive director of the DPC. “With DNA storage moving from the trial stage to practical implementation, we believe that it will be valuable for our members to evaluate this new differentiated storage medium, particularly with the opportunity to provide input on the initial offering.”

“We are pleased to join the Digital Preservation Coalition and are eager to be an active member of the group,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist. “We look forward to engaging with members to understand their needs for very long-term storage as we refine our Century Archive DNA data storage solution.”

About Twist Bioscience

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Legal Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Quarterly Report Form 10-Q filed with the Securities and Exchange Commission on February 9, 2022 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220228005319/en/